The Upregulation of GSTO2 is Associated with Colon Cancer Progression and a Poor Prognosis

Xingyu Peng, Jinfeng Zhu, Sicheng Liu, Zitao Liu, Chen Luo, Xun Wu, Zhonglin Yu, Zhengming ZhuJournal of Oncology 2023 · DOI

TL;DR

This study identifies Glutathione S-transferase omega 2 (GSTO2) as a key player in colon cancer progression. They found that higher GSTO2 levels are linked to more aggressive tumors and poorer patient outcomes, suggesting it could be a valuable prognostic marker. Furthermore, reducing GSTO2 levels in cancer cells experimentally inhibited their growth and migration.

What Problem Does This Paper Address?

Colorectal cancer (CRC) remains a significant cause of cancer-related mortality worldwide. While advancements in screening and early detection have helped, many patients are diagnosed at later stages, making prognosis and treatment challenging. Identifying reliable biomarkers that can predict disease progression and patient outcomes is crucial for improving clinical decision-making and developing targeted therapies. The role of Glutathione S-transferase omega 2 (GSTO2), a member of the GST family known to be involved in various cellular processes including cancer development, in colon cancer specifically, was not well understood. This paper aims to fill that knowledge gap by investigating GSTO2's expression, its correlation with clinical characteristics, and its impact on colon cancer progression and prognosis.

Methods

The researchers employed a multi-pronged approach to investigate GSTO2:

  • Bioinformatic Analysis: They utilized large-scale public datasets like The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) to analyze GSTO2 mRNA expression across various cancers and specifically in colon cancer. They also explored protein information from the Human Protein Atlas (HPA), GeneCards, and String databases.
  • Experimental Validation:
    • Western Blot and Immunohistochemistry (IHC): These techniques were used to confirm GSTO2 protein expression levels in colon cancer tissues and compare them with adjacent normal tissues.
  • Cell Culture and Manipulation: Human colon cancer cell lines (HT-29 and HCT-116) were used for in vitro experiments. RNA interference (siRNA) was employed to specifically reduce GSTO2 expression in these cells.
  • Proliferation Assays: Cell Counting Kit-8 (CCK-8) and 5-Ethynyl-2'-Deoxyuridine (EdU) assays were performed to measure the impact of GSTO2 knockdown on cancer cell proliferation.
  • Migration Assays: Wound healing assays and Transwell migration assays were conducted to assess the effect of GSTO2 silencing on cancer cell motility.
  • Statistical and Pathway Analysis:
    • Prognostic Analysis: Kaplan-Meier survival analysis and Cox regression analysis were used to determine the relationship between GSTO2 expression and patient survival, identifying independent risk factors.
  • Enrichment Analysis: Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analyses were performed on differentially expressed genes to understand the potential biological functions and pathways associated with GSTO2.
  • Immune Cell Infiltration Analysis: The CIBERSORT method was used to evaluate the composition of immune cells within the tumor microenvironment and its correlation with GSTO2 expression.

Datasets

  • The Cancer Genome Atlas (TCGA): Used for RNA sequencing data and clinical information of various cancer types, including colon cancer.
  • Genotype-Tissue Expression (GTEx) database: Used for RNA sequencing data of normal tissues.
  • Gene Expression Omnibus (GEO) database: Specific datasets (GSE38832, GSE40967, GSE17538) were downloaded for external validation of findings.
  • Human Protein Atlas (HPA): Used to explore GSTO2 protein expression levels.
  • GeneCards: Used to visualize the subcellular locations of GSTO2.
  • String database: Used to build protein-protein interaction networks.

Key Insights and Ideas

  • GSTO2 as a Pan-Cancer Overexpression: The study revealed that GSTO2 is significantly upregulated not just in colon cancer but across a broad spectrum of 15 different cancer types, highlighting its potential as a general oncogenic factor.
  • GSTO2's Role in Tumor Microenvironment (TME): Beyond direct effects on cancer cells, GSTO2 expression was found to correlate with the infiltration levels of various immune cells, suggesting it can modulate the tumor's immune landscape. This opens avenues for understanding how GSTO2 might influence treatment responses.
  • PI3K-Akt Pathway Involvement: GO and KEGG analyses pointed towards the PI3K-Akt signaling pathway as a key mechanism through which GSTO2 might promote colon cancer progression, a well-established pathway in cancer development.
  • GSTO2 as a Prognostic Indicator: The consistent finding of GSTO2 overexpression correlating with poorer survival across multiple analyses (TCGA, GEO) strongly supports its utility as a prognostic biomarker.

Key Results

  • GSTO2 is Overexpressed in Colon Cancer: Both mRNA and protein levels of GSTO2 were significantly higher in colon cancer tissues compared to normal adjacent tissues.
  • GSTO2 Expression Correlates with Poor Prognosis: High GSTO2 expression was significantly associated with advanced stages (Stage I vs. IV, Stage I vs. III, Stage II vs. IV), M classification (M1 vs. N0), and N classification (N2 vs. N1) of colon cancer.
  • Independent Risk Factor: Both univariate and multivariate Cox regression analyses identified GSTO2 as an independent risk factor for poor prognosis in colon cancer patients.
  • Inhibition of Cancer Cell Growth and Migration: Silencing GSTO2 in HT-29 and HCT-116 colon cancer cell lines significantly reduced their proliferation (measured by CCK-8 and EdU assays) and migration (measured by wound healing and Transwell assays).
  • Correlation with Immune Cells: GSTO2 expression showed significant correlations with several tumor-infiltrating immune cells, including CD8+ T cells, CD4+ memory T cells, and activated NK cells.

Limitations and Future Work

The authors acknowledge several limitations:

  • Reliance on Public Databases: A significant portion of the data was derived from public repositories, which are retrospective in nature. This can introduce potential biases.
  • Unclear Direct Mechanism: While the study identified GSTO2 as a risk factor and linked it to pathways like PI3K-Akt, the precise molecular mechanisms by which GSTO2 influences the occurrence and development of colon cancer remain to be fully elucidated.

Future work suggested by the authors includes:

  • Forward-Looking Research: Conducting prospective studies to mitigate biases associated with retrospective data.
  • Elucidating Direct Mechanisms: Further investigation into the specific molecular pathways and interactions through which GSTO2 exerts its effects on colon cancer cells and the tumor microenvironment.
  • Exploring GSTO2 as a Therapeutic Target: Given its role in cancer progression and its potential impact on the immune microenvironment, GSTO2 could be a candidate for targeted therapies.

Summary updated

Abstract

Colorectal cancer is the second-leading cause of cancer-related mortality in the United States. Glutathione S-transferase can affect the development of cancer. Glutathione S-transferase omega 2, a member of the GST family, plays an important role in many tumors. However, the role of Glutathione S-transferase omega 2 in the development of colon cancer remains unclear. Herein, our study aimed to investigate the exact role of Glutathione S-transferase omega 2 in colon cancer. We used RNA sequencing data from The Cancer Genome Atlas and the Genotype-Tissue Expression database to analyze Glutathione S-transferase omega 2 expressions. Then, we explore the protein information of Glutathione S-transferase omega 2 in the Human Protein Atlas, GeneCards, and String database. In addition, western blot and immunohistochemistry were performed to evaluate the protein levels of Glutathione S-transferase omega 2 in colon cancer tissues. We acquire data from the Gene Expression Omnibus and The Cancer Genome Atlas databases. Also, we performed relevant prognostic analyses of these data. In addition, we performed a statistical analysis of the clinical data from The Cancer Genome Atlas database and the expression level of Glutathione S-transferase omega 2. Then, we performed Cox regression analysis and found independent risk factors for prognosis in patients with colon cancer. The Kyoto Encyclopedia of Genes and Genomes and Gene Ontology enrichment analyses were used to explore the potential biological functions of Glutathione S-transferase omega 2. The infiltration of colon cancer-immune cells was evaluated by the CIBERSORT method. RNA silencing was performed using siRNA constructs in HCT-116 and HT-29 cell lines. Cell Counting Kit-8 and EdU assays were performed to determine cell proliferation. Transwell experiments and scratch tests were used to determine cell migration. As for the mRNA and protein expression levels of cells, we used quantitative real-time PCR and western blot to detect them. Our research shows that Glutathione S-transferase omega 2 is overexpressed in colon cancer patients, and this overexpression is associated with a poor prognosis. The high expression of Glutathione S-transferase omega 2 is significantly correlated stage with stage, M, and N classification progression in colon cancer by statistical analysis. Univariate and multivariate Cox regression analyses showed that Glutathione S-transferase omega 2 was an independent risk factor for poor prognosis in colon cancer. In addition, we also found that Glutathione S-transferase omega 2 expression levels can affect the immune microenvironment of colon cancer cells. Gene silencing of Glutathione S-transferase omega 2 in HT-29 and HCT-116 cells significantly inhibited tumor growth and migration. In summary, we found that Glutathione S-transferase omega 2 can be used as a molecular indicator of colon cancer prognosis. In vitro, gene silencing of Glutathione S-transferase omega 2 inhibited colon cancer cells' growth and migration.
BibTeX
@article{peng2023upregulation,
  author = {Xingyu Peng and Jinfeng Zhu and Sicheng Liu and Zitao Liu and Chen Luo and Xun Wu and Zhonglin Yu and Zhengming Zhu},
  title = {{The Upregulation of GSTO2 is Associated with Colon Cancer Progression and a Poor Prognosis}},
  journal = {Journal of Oncology},
  year = {2023},
  doi = {10.1155/2023/4931650},
}
Figure